Calidi Biotherapeutics targets Q1 2027 clinic entry for CLD-401 cancer programPUBT·13 hours agoCLDI+9.50%
Market Signals: How a USD 4.3B Pact and AI Capex Reshape Sector ExpectationsGlobal Report·1 day ago, 04:18 AMWPM+0.48%TTI-7.46%
The Biotech Survival Charade: Stop Buying the "AI Pivot" HypeGlobal Report·1 day ago, 04:14 AMINM-4.09%ONCY-1.49%
Inside the Biotech Sector's Recent Clinical Catalyst WaveGlobal Report·2 days ago, 04:17 AMGENB+2.09%IBRX-1.55%
Sector Watch: Wix's AI Overhaul and Crypto Pivots in Small-Cap SpaceGlobal Report·2 days ago, 04:13 AMCLDI+9.50%MASK-1.29%
The AI Spillover: How the Market's Edges are Rewiring Real InfrastructureGlobal Report·Jul 24 at 04:13 AMDXST-0.88%BRIA0.00%
Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value DriversUnusual Whales·Jul 21 at 07:10 AMCLDI+9.50%
Calidi Biotherapeutics adds former Genentech, Celgene executive Corsee Sanders to boardPUBT·Jul 21 at 07:03 AMCLDI+9.50%BMY+0.76%
12 Health Care Stocks Moving In Monday's After-Market Sessionbenzinga_article·Jul 20 at 04:05 PMMBAI-2.73%CPHI-19.08%
Calidi Biotherapeutics announces 1-for-16 reverse stock split effective July 31PUBT·Jul 20 at 03:30 PMCLDI+9.50%
Calidi Biotherapeutics Plans Relocation Through New Lease AgreementsTip Ranks·Jul 17 at 03:50 AMCLDI+9.50%
Calidi Biotherapeutics grants VP Finance inducement option for 100,000 shares at $0.15 exercise pricePUBT·Jul 8 at 03:07 PMCLDI+9.50%
Calidi Biotherapeutics director Corazon “Corsee” Sanders files initial beneficial ownership statementPUBT·Jun 29 at 04:13 PMCLDI+9.50%
